Albany on hold by Jefferies

Albany Molecular Research, Inc. was maintained by Jefferies & Co., Inc. analyst David Windley at a hold rating with a price target of $11.50. While the company's contract revenue improves, its profitability needs to improve as well to offset the Allegra erosion. Albany reported earnings per share of $0.06 on $43.4 million, versus Jefferies' estimates of $0.02 on $38.6 million in revenue. Shares of the Albany, N.Y., biopharmaceutical company were down $0.07 or 0.68%, at $10.30 on volume of 217,660 shares versus the three-month running average of 143,566 shares. (Nasdaq: AMRI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.